Latest Regulatory Clearance News

Horizon Oil confirms its takeover offer for Cue Energy shares as best and final, holding a majority stake and with all regulatory approvals cleared. The offer period closes on 19 June 2026, with liquidity risks flagged for minority shareholders who abstain.

Diamond Infraco has officially satisfied multiple regulatory conditions in its takeover offer for Atlas Arteria, freeing the offer from several major hurdles and holding a 34.56% stake.

ReNerve Limited has appointed UG Medical to distribute its NervAlign nerve repair products in Malaysia, tapping into a fast-growing healthcare market backed by government investment.

Heartland Group Holdings has agreed to acquire TSB Bank for NZD 620 million, merging the two into a challenger bank with $18 billion in assets and expected 20% EPS accretion.

Optiscan and Mayo Clinic have completed all key engineering milestones in their two-year partnership to develop a digital endomicroscopic imaging system for robotic surgery, extending their agreement to support further clinical and commercial planning.

Xingye Gold (Hong Kong) Mining Company Limited has launched an off-market takeover offer for all remaining shares in Far East Gold Ltd (ASX:FEG) at $0.13 cash per share, offering shareholders a premium amid stalled projects and funding concerns.

Qoria Limited is moving towards a transformative merger with US-based Aura Consolidated Group, Inc., combining complementary digital safety platforms and targeting growth through a $100 million capital raise and ASX listing.

EMVision's First Responder Brain Scanner has proven its operational feasibility in aeromedical settings with the Royal Flying Doctor Service, de-risking rural stroke diagnosis and supporting progression to commercial production.

Bremworth's acquisition by Floorscape faces further delay as the New Zealand Commerce Commission extends its clearance deadline to 30 June 2026, pushing the deal close to its expiry date.

Pacific Nickel Mines is pressing ahead with the sale of its Kolosori Nickel Project for a nominal A$1 while remaining suspended from the ASX, supported by ongoing Glencore financing and subject to key approvals.

Osteopore has secured Hainan FDA approval to clinically use and sell its custom orthopaedic devices at Shanghai Ruijin Hospital’s Hainan branch, marking a key step towards wider China market access. The company has scheduled its first patient surgery for June 2026.

SDI Limited has dispatched its Scheme Booklet to shareholders as it moves closer to a $1.40 per share acquisition by a Beijing Guoci subsidiary. The virtual shareholder meeting is set for 22 June 2026 with strong backing from the board and largest shareholder.